Helen Bell Gorrod
Research Assistant in Health Economics
The University of Sheffield
Regent Court, 30 Regent Street
Sheffield, S1 4DA
Tel: (+44) (0)114 222 0890
Fax: (+44) (0)114 222 0749
I joined the health Economics and Decision Science (HEDS) Group as a Research Assistant in 2014. My background is in economics. I previously worked at HM Treasury in the International Finance Directorate and completed my MSc and PhD in Economics at the University of Sheffield. My PhD thesis investigated the relationships between globalisation, productivity, knowledge and firm structure using UK firm-level data. This provided a strong grounding in micro-econometrics and quantitative analysis. I also have experience of teaching and lecturing in Economics and Statistics and assisting with STATA workshops. My main role in ScHARR is to participate in a project to analyse and employ statistical methods for adjusting survival estimates on datasets that are confounded by treatment crossover.
- Bell Gorrod H, Latimer NR, Damian D, Hettle R, Harty GT & Wong SL (2019) Impact of non-randomised dropout on treatment switching adjustment in the relapsing-remitting multiple sclerosis CLARITY trial and the CLARITY extension study. Value in Health, 22(7), 772-776. View this article in WRRO
- Turner J, Siriwardena AN, Coster J, Jacques R, Irving A, Crum A, Gorrod HB, Nicholl J, Phung V-H, Togher F , Wilson R et al (2019) Developing new ways of measuring the quality and impact of ambulance service care: the PhOEBE mixed-methods research programme. Programme Grants for Applied Research, 7(3). View this article in WRRO
- Bullement A, Latimer NR & Bell Gorrod H (2018) Survival Extrapolation in Cancer Immunotherapy: A Validation-Based Case Study. Value in Health. View this article in WRRO
- Durojaiye OC, Bell Gorrod H, Andrews D, Ntziora F & Cartwright K (2017) Clinical efficacy, cost-analysis and patient acceptability of outpatient parenteral antibiotic therapy (OPAT): a decade of Sheffield (UK) OPAT service. International Journal of Antimicrobial Agents. View this article in WRRO
- Latimer NR, Henshall C, Siebert U & Bell H (2016) Treatment Switching: statistical and decision making challenges and approaches. International Journal of Technology Assessment in Health Care, 32(3), 160-166. View this article in WRRO
- Latimer NR, Bell H, Abrams KR, Amonkar MM & Casey M (2016) Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy. Cancer Medicine, 5(5), 806-815. View this article in WRRO
- Bell Gorrod H, Kearns B, Stevens J, Thokala P, Labeit A, Latimer N, Tyas D & Sowdani A () A review of survival analysis methods used in NICE technology appraisals of cancer treatments: Consistency, limitations and areas for improvement. Medical Decision Making. View this article in WRRO
- Bell Gorrod H, Latimer N, Damian D, Hettle R, Harty GT & Wong SL () Assessing the long-term effectiveness of cladribine vs. placebo in the relapsing-remitting multiple sclerosis CLARITY randomized controlled trial and CLARITY Extension using treatment switching adjustment methods. Advances in Therapy.